Stock Taper
Exagen Inc. develops and commercializes diagnostic tests like AVISE for autoimmune diseases such as SLE and RA, aiding in diagnosis, prognosis, and monitoring through innovative complement activation and autoantibody assays.

Exagen's flagship diagnostic test enables early, accurate detection of complex autoimmune diseases like lupus, rheumatoid arthritis, and Sjögren's, driving company growth and revenue.
| Icon | PRODUCT | Q3-2025 | Q4-2025 | Q1-2026 | Q2-2026 |
|---|---|---|---|---|---|
![]() | Reportable Segment | $17.24M | $16.63M ▼ | $17.31M ▲ | $19.94M ▲ |
Overall rating: D+
| PEER | PRICE | |
|---|---|---|
ACRS | $6.41 | COMPARE |
SGHT | $8.26 | COMPARE |
NEO | $16.98 | COMPARE |
TKNO | $7.36 | COMPARE |
BIOA | $9.48 | COMPARE |
VNDA | $5.28 | COMPARE |
SMTI | $34.45 | COMPARE |
LFCR | $4.54 | COMPARE |